Equities Analysts Set Expectations for DVAX FY2024 Earnings

Dynavax Technologies Co. (NASDAQ:DVAX) – Research analysts at William Blair upped their FY2024 earnings estimates for Dynavax Technologies in a report released on Monday, January 13th. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will earn $0.16 per share for the year, up from their prior estimate of $0.15. The consensus estimate for Dynavax Technologies’ current full-year earnings is $0.19 per share.

A number of other research firms have also recently weighed in on DVAX. HC Wainwright upped their price objective on shares of Dynavax Technologies from $29.00 to $31.00 and gave the stock a “buy” rating in a research report on Tuesday. StockNews.com upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday.

Dynavax Technologies Stock Performance

NASDAQ:DVAX opened at $12.39 on Wednesday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The company has a fifty day moving average of $12.78 and a two-hundred day moving average of $11.66. The stock has a market capitalization of $1.63 billion, a PE ratio of 95.32 and a beta of 1.34. Dynavax Technologies has a fifty-two week low of $9.74 and a fifty-two week high of $14.30.

Institutional Investors Weigh In On Dynavax Technologies

A number of hedge funds have recently modified their holdings of DVAX. Rhumbline Advisers raised its position in shares of Dynavax Technologies by 1.8% in the second quarter. Rhumbline Advisers now owns 310,805 shares of the biopharmaceutical company’s stock valued at $3,490,000 after buying an additional 5,379 shares during the last quarter. Choreo LLC acquired a new stake in shares of Dynavax Technologies in the second quarter valued at about $363,000. State of New Jersey Common Pension Fund D acquired a new stake in shares of Dynavax Technologies in the second quarter valued at about $1,811,000. WINTON GROUP Ltd raised its position in shares of Dynavax Technologies by 9.3% in the second quarter. WINTON GROUP Ltd now owns 82,403 shares of the biopharmaceutical company’s stock valued at $925,000 after buying an additional 7,025 shares during the last quarter. Finally, Renaissance Technologies LLC raised its position in shares of Dynavax Technologies by 2.2% in the second quarter. Renaissance Technologies LLC now owns 2,478,178 shares of the biopharmaceutical company’s stock valued at $27,830,000 after buying an additional 53,600 shares during the last quarter. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.